Reveals a New Chemotherapeutic Modality for Refractory Gastric Cancer with Peritoneal Metastasis
Category Research
Writer 행정부서 (11) 윤정진
Date Modified Date : 2022.03.21 (Create Date : 2022.03.16)
View Count 131
Thumbnail /thumbnail.10079.jpg

A Research Team Led by Professor Jong-Han Kim Reveals a New Chemotherapeutic Modality for Refractory Gastric Cancer with Peritoneal Metastasis

A multicenter prospective study on intraperitoneal anticancer treatment in patients with stage 4 gastric cancer with peritoneal metastasis conducted for the first time in Korea

Confirms recommended dose and safety of anticancer drugs administered into the peritoneal space combined systemic chemotherapy



A research team led by Professor Jong-Han Kim from the Division of Gastroenterological Surgery at Korea University Guro Hospital announced the results of a new systemic & intraperitoneal chemotherapy that can improve the survival rate of gastric cancer patients with peritoneal metastasis.


Professor Kim's team conducted a phase 1 study of intraperitoneal paclitaxel and oral S-1/oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis. This study confirmed the recommended dose and safety of intraperitoneal paclitaxel administered with the systemic anticancer treatment.


Peritoneal metastasis is the most common type of metastasis and recurrence in patients with stage 4 advanced gastric cancer. In gastric cancer patients with distant metastasis, palliative systemic chemotherapy is the standard treatment, but even this has a very poor prognosis when peritoneal metastasis is present.


The research was a multicenter study involving more than 13 university hospitals in South Korea, and nine patients with stage 4 gastric cancer with peritoneal or distant metastasis received the treatment for approximately six months from June to December 2020. The subjects were divided into three groups to observe the progression after 40, 60, and 80 mg/㎡ of paclitaxel was administered into the peritoneal space respectively.


Phase I study confirmed that no serious side effects of grade 3 or higher were found in any of the patients participating in the study, and that peritoneal cancer index (PCI), which evaluates the degree of intraperitoneal metastasis decreased after chemotherapy.


Professor Kim said, "This research is a phase 1 multicenter study of intraperitoneal chemotherapy in stage 4 gastric cancer patients with peritoneal metastasis. Based on the results of this phase 1, a phase 2 study is currently implemented to prove its efficacy in enhancing survival. A phase 3 trial will be launched this year in order to confirm the survival rate compared to existing systemic chemotherapy."


He also said, "At present, only conventional palliative treatment is given to the gastric cancer patients with peritoneal metastasis because it is very difficult to treat and the benefit they could get from chemotherapy is very limited. Now, this study offers some hope for those patients with otherwise a fatal disease."


Professor Won Jun Seo from Korea University Guro Hospital and Professor Dong-Wook Kim from Dankook University Hospital participated as co-authors under the leadership of Professor Jong-Han Kim from Korea University Guro Hospital. Led by Professor You-Jin Jang, Korea University Guro Hospital along with 13 other centers in South Korea is currently running a phase 2 study. The results of the phase 1 study were published in the December 2021 issue of Journal of Gastric Cancer.

Answer